AGEN Stock Forecast: Agenus, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$5.97
−2.85% on the day

The median 12-month analyst price target for Agenus, Inc. is $25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 82 of 100 as at 21 Nov 2026 — inside the top quartile.

Market cap
$277.8M
Ticker Nerd rank
82/ 100
Median analyst target
$25
Analysts covering
3
Revenue$34.5M+34.4% y/y
Operating income$11.3M
Net income−$567K
Free cash flow−$31.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.4%
1M
−7.1%
YTD
+90.0%
1Y
+39.0%
From 52W high
−39.9%
From 52W low
+115.3%
$2.77
$9.93
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Agenus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
82/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
94
Quality
94
Growth
91
Momentum
84
Issuance
64
Revisions
34
Accruals
29
Volatility
24

Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (24): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00Jan 26Apr 26Jul 26Oct 26AGENHigh $40Median $25Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$16
Low
$25
Median
$40
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
9 Nov 2026B. Riley SecuritiesReiteratesBuy$14 → $16
26 Oct 2026Chardan CapitalMaintainsBuy$40
22 Oct 2026Chardan CapitalMaintainsBuy$40
5 Oct 2026Chardan CapitalMaintainsBuy$40
28 Sept 2026Rodman & RenshawInitiatesBuy$19
18 Sept 2026Chardan CapitalInitiatesBuy$40
11 Aug 2026HC Wainwright & Co.MaintainsBuy$30 → $25
30 July 2026B. Riley SecuritiesMaintainsBuy$8.00 → $14
13 July 2026HC Wainwright & Co.MaintainsBuy$23 → $30
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—
28 Aug 2025HC Wainwright & Co.ReiteratesBuy—
4 June 2025BairdMaintainsNeutral—
4 June 2025HC Wainwright & Co.UpgradeBuy—
13 May 2025BairdMaintainsNeutral—
13 May 2025HC Wainwright & Co.ReiteratesNeutral—
30 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
18 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
12 Mar 2025BairdMaintainsNeutral—
12 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
22 Jan 2025HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AGEN.

Market Radar

This page is one stock. Monday covers all of them.

AGEN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Agenus, Inc. returned +39.0% against +6.9% for the S&P 500, dividends included.

AGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26AGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−5.7%
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.2×

Cheaper than 33% of US stocks

Price / sales
2.0×

Cheaper than 48% of US stocks

Price / book
—
EV / EBITDA
4.1×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−93.9%

Higher than 3% of US stocks

Gross margin
57.2%

Higher than 70% of US stocks

Operating margin
38.9%

Higher than 92% of US stocks

Net margin
—
Returns & dividend
Return on equity
—
Return on assets
13.6%

Higher than 96% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Agenus, Inc. has a market value of $277.8M and an enterprise value of $223.6M.

  • Revenue in the twelve months to 30 June 2026: $132.7M. The latest quarter grew 34.4% year on year.

  • Net income over the same four quarters: $91.9M, a 69.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$98.5M.

  • Agenus, Inc. spent $54K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 44.8M.

  • Trailing P/E: 26.2×.

  • Agenus, Inc. employs 81 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

AGEN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AGENAgenus, Inc.$277.8M82
NAUTNautilus Biotechnology, Inc.$269.4M70
GALTGalectin Therapeutics, Inc.$271.3M82
PEPGPepGen Inc.$261.8M53
OCGNOcugen, Inc.$259.9M43
RLMDRelmada Therapeutics, Inc.$274.8M55
ALTAltimmune, Inc.$258.5M11

Take a look at AGEN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Agenus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AGEN

What is the AGEN stock price forecast for 2026-2027?

The median 12-month analyst price target for Agenus, Inc. is $25, with estimates ranging from $16 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AGEN stock a buy right now?

Of the 3 analysts covering Agenus, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agenus, Inc. 82 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AGEN?

As at 21 Nov 2026, Agenus, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).

Will AGEN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $25, and Ticker Nerd's factor model ranks Agenus, Inc. 82 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AGEN stock forecast for 2030?

No analyst covering Agenus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $40 over the next 12 months.

How has AGEN stock performed over the past year?

Agenus, Inc. returned +39.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Agenus, Inc. do?

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune system recognize and attack tumors.

Company

About Agenus, Inc.

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune system recognize and attack tumors. Its current portfolio also includes vaccine adjuvants and cell therapy programs, supported by proprietary discovery platforms and in-house manufacturing and clinical development capabilities. The company’s lead programs center on botensilimab and balstilimab, which are being advanced in multiple solid-tumor settings, including colorectal cancer and other difficult-to-treat cancers. Agenus also works through subsidiaries and partners to support adoptive cell therapies and adjuvant technologies, giving it a broad role across the immunotherapy value chain. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. remains a specialist developer in the cancer immunotherapy market.

CEO Dr. Garo H. Armen Ph.D. · 81 employees · United States · https://www.agenusbio.com